Table 3.

Univariate analysis of prognostic factors for RFS, OS, and LRFS in cervical cancer patients treated with post-surgical CCRT

	RFS				OS			LRFS
	n	3-year RFS (%)	95% CI (%)	p	3-year OS (%)	95% CI (%)	p	3-year LRFS (%)	95% CI (%)	p
Age (years)
< 42	45	71	55–82	0.535	86	72–94	0.814	82	67–90	0.863
≥ 42	51	80	66–89		94	83–98		94	83–98
Smoker
No	66	80	68–88	0.158	92	83–97	0.811	91	81–96	0.573
Yes	30	66	46–80		86	67–95		83	64–93
FIGO
IB–IIA	69	76	64–85	0.744	91	81–96	0.194	90	80–95	0.217
IIB	27	74	53–87		89	69–96		85	65–94
Course of chemotherapy
< 5	28	89	70–96	0.180	96	77–100	0.101	96	77–100	0.173
≥ 5	68	70	58–80		88	78–94		85	74–92
Parametrial invasion
No	47	78	64–88	0.396	94	81–98	0.345	89	76–95	0.317
Yes	49	73	58–83		87	74–94		88	74–94
Pelvic LNs
0–1	38	87	71–94	0.049	89	74–96	0.508	87	71–94	0.700
≥ 2	58	69	55–79		91	80–96		90	78–95
Histology
SCC	78	81	70–88	0.099	92	83–96	0.002	92	83–96	0.002
AD/ADS	18	55	29–74		83	57–94		72	46–87
Dissected LNs
< 40	43	72	55–83	0.498	86	71–93	0.533	81	66–90	0.322
≥ 40	53	79	65–88		94	83–98		94	83–98

RFS relapse-free survival, OS overall survival, LRFS locoregional relapse-free survival, CCRT concurrent chemoradiotherapy, FIGO International Federation of Gynecology and Obstetrics, LN lymph node, AD adenocarcinoma, ADS adenosquamous carcinoma